Targets of antibodies against Plasmodium falciparum-infected erythrocytes in malaria immunity.
Plasmodium falciparum is the major cause of malaria globally and is transmitted by mosquitoes. During parasitic development, P. falciparum-infected erythrocytes (P. falciparum-IEs) express multiple polymorphic proteins known as variant surface antigens (VSAs), including the P. falciparum erythrocyte...
| मुख्य लेखकों: | , , , , , , , , , , , , , , , |
|---|---|
| स्वरूप: | Journal article |
| भाषा: | English |
| प्रकाशित: |
2012
|
| _version_ | 1826290044593242112 |
|---|---|
| author | Chan, J Howell, K Reiling, L Ataide, R Mackintosh, C Fowkes, F Petter, M Chesson, J Langer, C Warimwe, G Duffy, M Rogerson, S Bull, P Cowman, A Marsh, K Beeson, J |
| author_facet | Chan, J Howell, K Reiling, L Ataide, R Mackintosh, C Fowkes, F Petter, M Chesson, J Langer, C Warimwe, G Duffy, M Rogerson, S Bull, P Cowman, A Marsh, K Beeson, J |
| author_sort | Chan, J |
| collection | OXFORD |
| description | Plasmodium falciparum is the major cause of malaria globally and is transmitted by mosquitoes. During parasitic development, P. falciparum-infected erythrocytes (P. falciparum-IEs) express multiple polymorphic proteins known as variant surface antigens (VSAs), including the P. falciparum erythrocyte membrane protein 1 (PfEMP1). VSA-specific antibodies are associated with protection from symptomatic and severe malaria. However, the importance of the different VSA targets of immunity to malaria remains unclear, which has impeded an understanding of malaria immunity and vaccine development. In this study, we developed assays using transgenic P. falciparum with modified PfEMP1 expression to quantify serum antibodies to VSAs among individuals exposed to malaria. We found that the majority of the human antibody response to the IE targets PfEMP1. Furthermore, our longitudinal studies showed that individuals with PfEMP1-specific antibodies had a significantly reduced risk of developing symptomatic malaria, whereas antibodies to other surface antigens were not associated with protective immunity. Using assays that measure antibody-mediated phagocytosis of IEs, an important mechanism in parasite clearance, we identified PfEMP1 as the major target of these functional antibodies. Taken together, these data demonstrate that PfEMP1 is a key target of humoral immunity. These findings advance our understanding of the targets and mediators of human immunity to malaria and have major implications for malaria vaccine development. |
| first_indexed | 2024-03-07T02:38:10Z |
| format | Journal article |
| id | oxford-uuid:a981b7ad-d8f9-498f-bf9b-3fc819ef547b |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T02:38:10Z |
| publishDate | 2012 |
| record_format | dspace |
| spelling | oxford-uuid:a981b7ad-d8f9-498f-bf9b-3fc819ef547b2022-03-27T03:08:59ZTargets of antibodies against Plasmodium falciparum-infected erythrocytes in malaria immunity.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:a981b7ad-d8f9-498f-bf9b-3fc819ef547bEnglishSymplectic Elements at Oxford2012Chan, JHowell, KReiling, LAtaide, RMackintosh, CFowkes, FPetter, MChesson, JLanger, CWarimwe, GDuffy, MRogerson, SBull, PCowman, AMarsh, KBeeson, JPlasmodium falciparum is the major cause of malaria globally and is transmitted by mosquitoes. During parasitic development, P. falciparum-infected erythrocytes (P. falciparum-IEs) express multiple polymorphic proteins known as variant surface antigens (VSAs), including the P. falciparum erythrocyte membrane protein 1 (PfEMP1). VSA-specific antibodies are associated with protection from symptomatic and severe malaria. However, the importance of the different VSA targets of immunity to malaria remains unclear, which has impeded an understanding of malaria immunity and vaccine development. In this study, we developed assays using transgenic P. falciparum with modified PfEMP1 expression to quantify serum antibodies to VSAs among individuals exposed to malaria. We found that the majority of the human antibody response to the IE targets PfEMP1. Furthermore, our longitudinal studies showed that individuals with PfEMP1-specific antibodies had a significantly reduced risk of developing symptomatic malaria, whereas antibodies to other surface antigens were not associated with protective immunity. Using assays that measure antibody-mediated phagocytosis of IEs, an important mechanism in parasite clearance, we identified PfEMP1 as the major target of these functional antibodies. Taken together, these data demonstrate that PfEMP1 is a key target of humoral immunity. These findings advance our understanding of the targets and mediators of human immunity to malaria and have major implications for malaria vaccine development. |
| spellingShingle | Chan, J Howell, K Reiling, L Ataide, R Mackintosh, C Fowkes, F Petter, M Chesson, J Langer, C Warimwe, G Duffy, M Rogerson, S Bull, P Cowman, A Marsh, K Beeson, J Targets of antibodies against Plasmodium falciparum-infected erythrocytes in malaria immunity. |
| title | Targets of antibodies against Plasmodium falciparum-infected erythrocytes in malaria immunity. |
| title_full | Targets of antibodies against Plasmodium falciparum-infected erythrocytes in malaria immunity. |
| title_fullStr | Targets of antibodies against Plasmodium falciparum-infected erythrocytes in malaria immunity. |
| title_full_unstemmed | Targets of antibodies against Plasmodium falciparum-infected erythrocytes in malaria immunity. |
| title_short | Targets of antibodies against Plasmodium falciparum-infected erythrocytes in malaria immunity. |
| title_sort | targets of antibodies against plasmodium falciparum infected erythrocytes in malaria immunity |
| work_keys_str_mv | AT chanj targetsofantibodiesagainstplasmodiumfalciparuminfectederythrocytesinmalariaimmunity AT howellk targetsofantibodiesagainstplasmodiumfalciparuminfectederythrocytesinmalariaimmunity AT reilingl targetsofantibodiesagainstplasmodiumfalciparuminfectederythrocytesinmalariaimmunity AT ataider targetsofantibodiesagainstplasmodiumfalciparuminfectederythrocytesinmalariaimmunity AT mackintoshc targetsofantibodiesagainstplasmodiumfalciparuminfectederythrocytesinmalariaimmunity AT fowkesf targetsofantibodiesagainstplasmodiumfalciparuminfectederythrocytesinmalariaimmunity AT petterm targetsofantibodiesagainstplasmodiumfalciparuminfectederythrocytesinmalariaimmunity AT chessonj targetsofantibodiesagainstplasmodiumfalciparuminfectederythrocytesinmalariaimmunity AT langerc targetsofantibodiesagainstplasmodiumfalciparuminfectederythrocytesinmalariaimmunity AT warimweg targetsofantibodiesagainstplasmodiumfalciparuminfectederythrocytesinmalariaimmunity AT duffym targetsofantibodiesagainstplasmodiumfalciparuminfectederythrocytesinmalariaimmunity AT rogersons targetsofantibodiesagainstplasmodiumfalciparuminfectederythrocytesinmalariaimmunity AT bullp targetsofantibodiesagainstplasmodiumfalciparuminfectederythrocytesinmalariaimmunity AT cowmana targetsofantibodiesagainstplasmodiumfalciparuminfectederythrocytesinmalariaimmunity AT marshk targetsofantibodiesagainstplasmodiumfalciparuminfectederythrocytesinmalariaimmunity AT beesonj targetsofantibodiesagainstplasmodiumfalciparuminfectederythrocytesinmalariaimmunity |